Blogs

Latest Blogs

[wd_asp id=2]

GMP Potency Assays: Technologies & Validation Guide

July 2, 2026

Following up on our previous GMP blog “GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions”, this article explores GMP potency assays, including…

Building a bioanalytical workflow for a vaccine study: The key assays and considerations

March 12, 2025

The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…

Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach

March 5, 2025

Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…

The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions

February 18, 2025

CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…

Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials

October 18, 2024

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…

Allogeneic CAR T cell therapies: A major step forward

October 9, 2024

In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…

A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology

September 17, 2024

Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…